- Home
- SAVA vs ADAG Comparison
SAVA vs ADAG Comparison
Compare SAVA & ADAG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SAVA
- ADAG
- Stock Information
- Founded
- SAVA 1998
- ADAG 2011
- Country
- SAVA United States
- ADAG China
- Employees
- SAVA 30
- ADAG N/A
- Industry
- SAVA Biotechnology: Pharmaceutical Preparations
- ADAG Biotechnology: Pharmaceutical Preparations
- Sector
- SAVA Health Care
- ADAG Health Care
- Exchange
- SAVA Nasdaq
- ADAG Nasdaq
- Market Cap
- SAVA 70.5M
- ADAG 81.9M
- IPO Year
- SAVA N/A
- ADAG 2021
- Fundamental
- Price
- SAVA $1.57
- ADAG $1.42
- Analyst Decision
- SAVA Buy
- ADAG Strong Buy
- Analyst Count
- SAVA 3
- ADAG 1
- Target Price
- SAVA $54.50
- ADAG $8.00
- AVG Volume (30 Days)
- SAVA 1.2M
- ADAG 29.9K
- Earning Date
- SAVA 05-09-2025
- ADAG 03-24-2025
- Dividend Yield
- SAVA N/A
- ADAG N/A
- EPS Growth
- SAVA N/A
- ADAG N/A
- EPS
- SAVA N/A
- ADAG N/A
- Revenue
- SAVA N/A
- ADAG $103,204.00
- Revenue This Year
- SAVA N/A
- ADAG $6,488.89
- Revenue Next Year
- SAVA N/A
- ADAG $57.50
- P/E Ratio
- SAVA N/A
- ADAG N/A
- Revenue Growth
- SAVA N/A
- ADAG N/A
- 52 Week Low
- SAVA $1.15
- ADAG $1.33
- 52 Week High
- SAVA $42.20
- ADAG $3.58
- Technical
- Relative Strength Index (RSI)
- SAVA 45.15
- ADAG 39.32
- Support Level
- SAVA $1.37
- ADAG $1.36
- Resistance Level
- SAVA $1.73
- ADAG $1.92
- Average True Range (ATR)
- SAVA 0.13
- ADAG 0.13
- MACD
- SAVA 0.08
- ADAG -0.00
- Stochastic Oscillator
- SAVA 76.72
- ADAG 13.79
About SAVA Cassava Sciences Inc.
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease; and investigational diagnostic product candidate is called SavaDx and it is a novel way to detect the presence of Alzheimer's disease from a small sample of blood, possibly years before the overt appearance of clinical symptoms. It is currently conducting two randomized placebo-controlled Phase 3 clinical trials of oral simufilam in patients with Alzheimer's disease dementia. It has one business segment: the development of novel drugs and diagnostics.
About ADAG Adagene Inc.
Adagene Inc platform-driven, clinical-stage biopharmaceutical company engaged in transforming the discovery and development of novel antibody-based cancer immunotherapies. It is principally engaged in research, development and production of monoclonal antibody drugs for cancers. The company's platform is designed to generate therapeutic antibody candidates with functional epitopes and species cross-reactivity as highlighted by the company's immunotherapy pipeline.